In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Inari Medical (NARI – Research Report), with a price target of $100.00. The company’s shares closed last Wednesday at $81.68.
According to TipRanks.com, Thibault is a 4-star analyst with an average return of 8.1% and a 34.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.
Currently, the analyst consensus on Inari Medical is a Strong Buy with an average price target of $99.00.
The company has a one-year high of $100.00 and a one-year low of $50.50. Currently, Inari Medical has an average volume of 651.7K.
Based on the recent corporate insider activity of 95 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NARI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
Read More on NARI: